Raven Biotechnologies

Raven Biotechnologies
South San Francisco, Calif.
Founded: 1999

Why It's Fierce: Raven is identifying antibody drug targets that are overlooked by most research techniques. The company's technology accounts for cellular interactions, offering researchers a more accurate technique for pairing monoclonal antibodies with specific antigens on the cell surface. With $40 million in fresh financing, Raven has the financial resources to fund human studies of its lead products.

What to look for in 2003: The company will announce its first clinical development candidates over the coming months.

Raven Biotechnologies

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.